Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy

Table 6 Differences in biological and clinical aging markers between miRNA-based patient clusters at inclusion

Aging/frailty parameter	Statistic	Patient cluster A	Patient cluster B	p-value
Calendar age	N	43	45
Calendar age	Mean ± SD	76.5 ± 5.2	73.8 ± 3.1	0.018
BALDUCCI
Fit	n/N (%)	9/43 (20.9%)	12/44 (27.3%)
Vulnerable	n/N (%)	12/43 (27.9%)	16/44 (36.4%)
Frail	n/N (%)	22/43 (51.1%)	16/44 (36.4%)	0.378
LOFS	N	42	44
LOFS	Mean ± SD	6.9 ± 2.2	7.7 ± 1.7	0.119
G8-total	N	43	45
G8-total	Mean ± SD	14.1 ± 1.8	14.2 ± 2.1	0.571
fTRST	N	36	30
fTRST	Mean ± SD	2.3 ± 1.0	1.8 ± 0.9	0.046
Telomere length (T/S ratio)	N	33	38
Telomere length (T/S ratio)	Mean ± SD	0.67 ± 0.17	0.74 ± 0.28	0.423
IL-6 ^a (pg/mL)	N	43	45
IL-6 ^a (pg/mL)	Median (IQR)	4.3 (2.4; 6.4)	1.7 (1.0; 3.3)	< 0.001
IL-10 (pg/mL)	N	41	43
IL-10 (pg/mL)	Mean ± SD	0.26 ± 0.25	0.25 ± 0.30	0.528
IGF-1 (pg/mL)	N	43	45
IGF-1 (pg/mL)	Mean ± SD	73 ± 24	79 ± 24	0.308
TNFα (pg/mL)	N	43	45
TNFα (pg/mL)	Median (IQR)	1.5 (0.9; 2.3)	1.2 (0.7; 1.6)	0.032
MCP-1 (pg/mL)	N	43	45
MCP-1 (pg/mL)	Mean ± SD	197 ± 90	146 ± 57	< 0.001
RANTES (ng/mL)	N	43	45
RANTES (ng/mL)	Mean ± SD	52 ± 42	64 ± 47	0.179

^aFor IL-6 and TNFα, median and IQR was used instead of mean ± SD, to moderate the effect of outliers
p-values < 0.05 are marked in bold

ISSN: 1471-2407